

Supplemental online content for:

Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments

J. Matt McCrary, PhD; David Goldstein, MBBS, FRCP, FRACP; Terry Trinh, PhD; Hannah C. Timmins, BSc(Hons); Tiffany Li, MBiostat; Jasmine Menant, PhD; Michael Friedlander, MBChB(Hons), PhD, MRCP, FRACP; Craig R. Lewis, MBBS, MMed, FRACP; Mark Hertzberg, MBBS, PhD, FRACP, FRCPA; Siobhan O'Neill, MBBS, FRACP; Tracy King, RN, MN; Annmarie Bosco, MBBS, FRACP, FRCPA; Michelle Harrison, MBBS(Hons), FRACP; and Susanna B. Park, PhD

J Natl Compr Canc Netw 2019;17(8):949–955

eTable 1: Relationships Between Postural Sway and Individual Assessment or Demographic Items

eTable 2: Multiple Regression Analysis of 5 Key Correlates of Postural Sway Sumscore and Patient-Reported Disability

eTable 1. Relationships Between Postural Sway and Individual Assessment or Demographic Items				
	Assessment Item	R	P Value	n^a
Patient-reported balance/mobility deficit	CIPN20 #9	0.51	3.6×10 ⁻¹⁴	49
Patient-reported numbness/tingling ^b	CIPN20 #1-4	0.51	8.7×10 ⁻¹⁴	—
Patient-reported fine motor deficit (pen)	CIPN20 #11	0.46	1.9×10 ⁻¹¹	40
Numbness/Tingling (clinical) ^b	TNSc #1	0.46	1.6×10 ⁻¹⁰	—
Patient-reported leg weakness	CIPN20 #15	0.44	3.0×10 ⁻¹⁰	47
Abnormal vibration perception	TNSc #4	0.42	1.4×10 ⁻⁹	54
Age ^b	—	0.41	5.4×10 ⁻⁹	—
Patient-reported fine motor deficit (buttons)	CIPN20 #12	0.40	1.2×10 ⁻⁸	70
Weakness (clinical)	TNSc #2	0.34	2.0×10 ⁻⁶	48
Patient-reported shooting/burning pain	CIPN20 #5-6	0.30	2.0×10 ⁻⁵	47
Patient-reported postural hypotension	CIPN20 #16	0.29	5.9×10 ⁻⁵	57
Abnormal tendon reflex	TNSc #6	0.28	9.6×10 ⁻⁵	101
Patient-reported hand weakness	CIPN20 #13	0.27	.00017	69
Patient-reported cramps	CIPN20 #7-8	0.27	.00022	57
Patient-reported foot drop	CIPN20 #14	0.24	.001	29
Patient-reported hearing difficulty	CIPN20 #18	0.24	.001	44
Patient-reported temperature detection deficit	CIPN20 #10	0.19	.01	19
Abnormal pinprick perception	TNSc #3	0.17	.02	100
Confirmed diabetes diagnosis ^b	—	0.09	.23	—
Patient-reported blurred vision	CIPN20 #17	0.08	.30	34
Sex ^b	—	0.07	.32	—
Strength (clinical—manual muscle test)	TNSc #5	0.07	.36	16
Time since completion of neurotoxic cancer treatment ^b	—	0.04	.56	—

Abbreviations: CIPN, chemotherapy-induced peripheral neuropathy; CIPN20, EORTC QLQ-CIPN20 questionnaire; TNSc, Total Neuropathy Score clinical version. Black dashed line denotes critical $\alpha=0.00625$.

^aNumber of positive/abnormal responses to each item (out of N=190 patients); not applicable to continuous variables.

^bContinuous variable.

eTable 2. Multiple Regression Analysis of 5 Key Correlates of Postural Sway Sumscore and Patient-Reported Disability

	Assessment Item	R	β	P Value ^a
Full model		0.75		<.001
Patient-reported leg weakness	CIPN20 #15	0.66	-0.45	<.001
Patient-reported balance/mobility deficit	CIPN20 #9	0.72	-0.24	<.001
Age (≥ 65 years)		0.74	0.18	.002
Patient-reported numbness/tingling	CIPN20 #1-4	0.75	0.20	.014
Abnormal vibration perception	TNSc #4			.75

Abbreviations: CIPN, chemotherapy-induced peripheral neuropathy; CIPN20, EORTC QLQ-CIPN20 questionnaire; TNSc, Total Neuropathy Score clinical version. ^aP values correspond to the significance of β weights.